RxDoctor Payments Data

Brin Freund, MD

Epilepsy · Jacksonville, FLNPI 1093151813

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AbbVie at 42.6% of the total. 2025 is the largest year on record at $7,679, more than ten times the $476 reported in 2019.

$17,817in general payments, 2019–2025

Across 49 payments — averaging $363.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$8K
  • UCB, Inc.$7K
  • Novartis$2K
  • SK Life Science, Inc.$365
  • Cadwell Industries, Inc$156
  • Clearpoint Neuro, Inc.$149
  • plus $170 from 3 others

What the payments were for

  • Consulting fees$7,99545%
  • Speaking & faculty fees$5,75032%
  • Travel & lodging$1,72010%
  • Food & beverage$1,96111%
  • Education$3912%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)30$7,587
UCB, Inc.9$7,156
Novartis1$2,235
SK Life Science, Inc.4$365
Cadwell Industries, Inc1$156
Clearpoint Neuro, Inc.1$149
Medtronic1$87
Neurelis, Inc.1$43
Neuroone Medical Technologies Corporation1$41

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,817 in reported general payments places this provider in the 65th percentile of 23 epilepsy providers in Florida.

See all epilepsy providers in Florida

Medicare billing

Part B allowed, 2024
$39,351
Medicare patients
220
Services billed
311

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate32$59,789
Lacosamide43$17,706
Levetiracetam22$901
Levetiracetam ErLevetiracetam14$785
Lamotrigine23$612
Clobazam19$585
Zonisamide15$491
Clonazepam11$160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$365$59,78932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 23 epilepsy providers in Florida.

Other epilepsy in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →